Navigation Links
New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
Date:10/25/2008

rienced a reduction in disease signs and symptoms at one year compared with patients treated with placebo plus methotrexate. At 52 weeks, 56 percent, 36 percent and 20 percent of RA patients treated with ACTEMRA 8 mg/kg plus methotrexate achieved ACR20, ACR50 and ACR70(2), respectively, and 47 percent, 29 percent and 16 percent of patients in the ACTEMRA 4 mg/kg arm achieved these ACR scores, respectively. In contrast, 25 percent, 10 percent and 4 percent of patients in the control group achieved ACR20, ACR50 and ACR70, respectively. Disease remission (DAS28 <2.6)(3) was demonstrated in 47 percent and 30 percent of patients treated with ACTEMRA 8 mg/kg and 4 mg/kg, respectively, at week 52 compared with 8 percent of patients treated with placebo plus methotrexate.

"We've seen in previous studies that patients treated with ACTEMRA experienced an improvement in the signs and symptoms of RA and achieved remission according to the DAS28 criteria more often than with DMARDs," said Kenneth Bahrt, M.D., Global Medical Director, Autoimmunity, Roche. "The LITHE study not only confirmed these data, but for the first time demonstrated that ACTEMRA also significantly inhibited the progression of structural joint damage in patients with RA."

At one year, the study also showed that there was improved physical function following treatment with ACTEMRA, as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI).(4)

About the LITHE Study

LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage), a three-arm, randomized, double-blind, placebo-controlled study, was designed to evaluate the efficacy and safety of ACTEMRA (8 mg/kg or 4 mg/kg) plus methotrexate compared with placebo plus methotrexate in RA patients for the prevention of structural joint damage, improvement in physical function and disease signs and symptoms. Patients received either ACTEMRA

intravenously every four weeks plus methotrexate weekly or place
'/>"/>

SOURCE Hoffmann-La Roche Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
3. Life Recovery Systems Receives NIH Grant to Study Expanded Use of Its ThermoSuit System
4. Mindset Media Study Reveals Which Independent Voters Favor Obama Vs. McCain
5. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
6. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
7. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
8. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
9. Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques
10. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
11. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Depomed, Inc. (NASDAQ: ... release second quarter fiscal year 2014 financial results after ... will host a conference call beginning at 4:30 pm ... can access the call by dialing 877-317-6789 ( ... call will also be available via a live webcast ...
(Date:7/25/2014)... 25, 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) is ... Understanding ("MOU") with LaurelCo, LLC, an Illinois ... both cultivation and dispensary medical marijuana licenses in the state ... GBLX will acquire a 20% equity interest in LaurelCo, LLC ... growing chambers, as well as all technology related to ...
(Date:7/25/2014)... 25, 2014 According to a ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, ... Growth, Trends and Forecast (Value and Volume), 2013 - ... 19.99 billion in 2012 and is expected to grow ... to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... NEW ORLEANS, July 24 There are a ... according to a new,report released here today during ... mental illnesses have on patients, their families,and society. ... The briefing, led by the Pharmaceutical Research and ...
... 24 MacroChem Corporation (OTC,Bulletin Board: MACM) today ... 37 patients who completed a 48-week, U.S. multi-center,open-label ... antifungal,lacquer for the treatment of onychomycosis (nail fungus). ... "complete cure" defined as,negative mycology (negative fungal culture ...
Cached Medicine Technology:More Than 300 New Medicines Being Developed for Mental Illnesses 2More Than 300 New Medicines Being Developed for Mental Illnesses 3More Than 300 New Medicines Being Developed for Mental Illnesses 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5
(Date:7/26/2014)... 2014 The European Artificial lift market report ... analysis and forecast of revenue. The artificial lift market in ... 2013 to around $5.4 billion by 2018, at a CAGR ... the TOC of European artificial lift market report, to get ... glimpse of the segmentation in European Artificial lift market, and ...
(Date:7/26/2014)... Recently, iFitDress.com, a popular supplier of wedding dresses and ... range of high quality party outfits. Additionally, it has ... they are now provided at discounted prices, up to ... the leading suppliers in the international market. According to ... dresses have flattering looks and fine craftsmanship. They ...
(Date:7/26/2014)... News) -- Pools can provide much-needed relief from the ... they swallow too much chlorinated water, experts warn. ... ones to get water in their mouth. Some kids ... warnings from their parents. Although swallowing a small ... parents to realize that ingesting too much can lead ...
(Date:7/26/2014)... 2014 As reported by Lauren ... based on 3 factors: smaller spaces, multi-generational access, and ... trend of 2014 lists, including this article on ... Amerec , a leading manufacturer of steam bath generators, ... due to smaller spaces and an effort to reduce ...
(Date:7/26/2014)... New York, NY (PRWEB) July 26, 2014 ... by Infosecurity magazine on July 23rd, new research by ... are starting to rewrite their playbook, now focusing more ... individuals en masse who have become increasingly wise to ... (GDF) founder and CEO/CTO, Joe Caruso, talks about ...
Breaking Medicine News(10 mins):Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:High Quality Wholesale Party Dresses Online at iFitDress.com 2Health News:Don't Let Kids Drink Pool Water 2Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6
... April 3 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,Corp. (NASDAQ: NCST ... will,step down as Vice President Finance & Administration and ... another company in a field,unrelated to any of NUCRYST,s ... search for Mr. Lurier,s successor., "On behalf of ...
... April 3 /PRNewswire-FirstCall/ - SXC Health Solutions, Corp.,("SXC" or ... leading provider of,pharmacy benefits management services, announces that Mark ... CFO, will present at the,SunTrust 37th Annual Institutional Conference ... place on Tuesday, April 15,2008 at 9:40 am Eastern ...
... FRANCISCO, Calif., April 3, 2008 ,Renovis, Inc. (Nasdaq: ... the,discovery and development of drugs for major medical ... announced today that the waiting,period under the Hart-Scott-Rodino ... without the United States Federal Trade Commission,requesting additional ...
... 2008 Medical Records Institute (MRI),announces a new ... will be announced at the TEPR 2008 opening ... This new TEPR Award is the first ... their products meet a range of EMR medicolegal,requirements, ...
... half just occasionally had too much , , THURSDAY, April 3 ... are habitual drinkers, but new research suggests that people who ... who drive while intoxicated. , When it comes to drunk ... said study author Dr. Nicole T. Flowers, a medical epidemiologist ...
... Lubbock, TX April 3, 2008 Patients with genital ... served by healthcare providers who initiate positive discussions about them, ... Womens Health. , Yet, too often, such discussions ... related to the piercings, due to healthcare providers uneasiness over ...
Cached Medicine News:Health News:NUCRYST Announces Senior Management Change 2Health News:NUCRYST Announces Senior Management Change 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 2Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 4Health News:Medical Records Institute Announces New TEPR Award for EMRs Best Meeting Medicolegal Requirements 2Health News:Alcoholics Not to Blame for All Drunk Driving Cases 2
... Radiopaque Bone Cement consists of ... sterile,ampule containing bone cement liquid ... a sterile polyethylene bag,containing bone ... pouch. The interiors of the ...
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
A "doughy" type of bone cement intended for manual application....
... technology, such as a recessed scratch-resistant sapphire ... housings, this arthroscope has superior clarity and ... Steris and steam autoclaving or soaked in ... to fit ACMI, Wolf, Dyonics and Storz ...
Medicine Products: